Article Text

Download PDFPDF
Targeting activated T cells: successful use of anti-CD25 monoclonal antibody basiliximab in a patient with systemic sclerosis
  1. H U Scherer,
  2. G-R Burmester,
  3. G Riemekasten
  1. Department of Rheumatology and Clinical Immunology, Charité—University Medicine Berlin, Berlin, Germany
  1. Correspondence to:
    H U Scherer
    Department of Rheumatology and Clinical Immunology, Charité—University Medicine Berlin, Schumannstrasse 20-21, 10117 Berlin, Germany; ulrich.scherer{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Serum levels of soluble interleukin (IL) 2 receptor strongly correlate with skin involvement, disease progression and mortality in systemic sclerosis (SSc).1,2 This finding underlines the role of activated and possibly dysregulated T cells in the pathogenesis of the disease. Specifically targeting these cells may therefore be a new therapeutic approach. Basiliximab is a chimeric monoclonal antibody directed against the α chain (CD25) of the IL2 receptor.3 It is approved for the treatment of kidney allograft rejections. Here, we describe the successful use of basiliximab in combination with cyclophosphamide in a patient with severe, rapidly progressive SSc.

In February 2004, a 43-year-old woman with a 3-year history of Scl-70-positive, diffuse SSc presented to our department. Despite prior treatment with methotrexate, prostacycline infusions, azathioprine and calcium channel blockers, the patient presented with severe Raynaud’s phenomenon, digital ulcers (fig 1A) …

View Full Text


  • Competing interests: None declared.